Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 99K | 207K | 146K | 63K | 27K |
| Gross Profit | 62K | 127K | 103K | 50K | 24K |
| Operating Income | -2M | -3M | -2M | -2M | -1M |
| EBITDA | -1M | -3M | -2M | -2M | -1M |
| Net Income | -2M | -4M | -3M | -2M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
-50.00%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Therapeutic Solutions International, Inc. (TSOI) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 50.0% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -52.1%, EPS growth of +53.3%, a dividend yield of 0.0%. What stands out right now is revenue -52.1%, EPS +53.3%, free cash flow -5.2% with operating margin -2006.7% and ROIC -91.5%. Valuation sits in the middle of the pack at price/sales 5.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TSOI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TSOI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TSOI Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TSOI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$27.5K
-56.1% YoY
FY Net Income
-$1.7M
+22.8% YoY
Free Cash Flow
-$310.7K
+53.5% YoY
Revenue Growth
-52.1%
EPS Growth
+53.3%
Gross Margin
62.9%
Net Margin
-2191.9%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 99K | 207K | 146K | 63K | 27K |
| Gross Profit | 62K | 127K | 103K | 50K | 24K |
| Operating Income | -2M | -3M | -2M | -2M | -1M |
| EBITDA | -1M | -3M | -2M | -2M | -1M |
| Net Income | -2M | -4M | -3M | -2M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 28K | 18K | 94K | 252K | 26K |
| Total Assets | 3M | 4M | 2M | 603K | 311K |
| Total Liabilities | 2M | 2M | 3M | 2M | 2M |
| Shareholder Equity | 1M | 1M | -805K | -2M | -2M |
| Total Debt | 888K | 1M | 1M | 1M | 982K |
| Net Debt | 860K | 1M | 1M | 788K | 955K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
311K
+53.1% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
311K
+53.5% YoY
Key ratios
Gross Margin
62.9%
Operating Margin
-2006.7%
Net Margin
-2191.9%
ROE
-184.9%
Debt / Equity
0.79x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.